Skip to content

Comparison of fluoro-18-labeled quinoline PSMA (18F-PSMA-7Q) and 18F-PSMA-1007 in PET imaging of prostate cancer

Comparison of fluoro-18-labeled quinoline PSMA (18F-PSMA-7Q) and 18F-PSMA-1007 in PET imaging of prostate cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200065077
Enrollment
Unknown
Registered
2022-10-27
Start date
2022-10-27
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Interventions

Gold Standard:1. Reference standard for primary prostate cancer: gold standard for histopathological diagnosis 2. Patients with postoperative biochemical recurrence of prostate cancer: senior physicia
Index test:18F -PSMA-7Q

Sponsors

Chinese PLA General Hosptial
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Primary prostate cancer: 1 patients older than 40 years old and less than 85 years old; 2PSA and routine imaging examination showed that PCa;3 planned to carry out puncture biopsy in our hospital to obtain pathological results (type, location, Gleason grade and score, etc.). 2.Patients with postoperative biochemical recurrence of prostate cancer: (1) more than 40 years old and less than 85 years old; (2) patients with serum PSA level >= 0.2ng/ml after radical prostatectomy; (3) patients who received endocrine therapy or radiation therapy after two PET/CT examinations.

Exclusion criteria

Exclusion criteria: 1. Primary prostate cancer: (1) patients who could not tolerate PET/CT examination; (2) patients who planned to have a puncture biopsy between two examinations. 2. The exclusion criteria of patients with biochemical recurrence of prostate cancer after operation were as follows: (1) patients who could not tolerate PET/CT examination; (2) patients who planned to receive endocrine therapy or radiotherapy within one week.

Design outcomes

Primary

MeasureTime frame
The number of lesions and their SUV value;Diagnostic efficacy of prostate cancer;Sensitivity;Specificity;positive predictive value;negative predictive value;

Countries

China

Contacts

Public ContactJinming Zhang

Chinese PLA General Hospital

zhangjm301@163.com13801210291

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026